[Experimental therapy with angiogenesis inhibitor TNP-470 on human ovarian cancer transplanted subcutaniously in nude mice].
OBJECTIVE
To study the effect of an angiogenesis inhibitor TNP-470 (TNP) used alone and in combination with cytoxan (CTX) in the treatment of human ovarian cancer transplanted s.c. in nude mice.


METHODS
Human ovarian cancer transplanted s.c. in nude mice model was established, then divided into 5 groups: control group, vehicle group, TNP group, CTX group and TNP + CTX group, different treatments were served from day 8 after transplantation and all mice were sacrificed after 28 days. The weights of the mice and the volumes of the tumors were measured respectively during the therapy time. Moreover, microscopy was done after H&E staining.


RESULTS
The growth inhibiting rates in the TNP and CTX group were 26.1% and 33.9% respectively; After combined, the rate was increased to 70.5%. There were no obvious decrease in the weight of all treated mice.


CONCLUSIONS
Treatment with TNP is an potentially useful method of antitumor therapy in ovarian cancer, although the inhibition effects were not obvious in small doses. Moreover, TNP could enhance the effectiveness of antitumor drug.
Kong
Haihong
H
Department of Obstetrics and Gynecology, 411 Hospital of People's Liberation Army, Shanghai 200081, China.
Jin
Zhijun
Z
Yao
Ming
M
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001835:Body Weight / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D003510:Cyclohexanes; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004357:Drug Synergism; D005260:Female; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012717:Sesquiterpenes / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
D020533:Angiogenesis Inhibitors; D018906:Antineoplastic Agents, Alkylating; D003510:Cyclohexanes; D012717:Sesquiterpenes; D003520:Cyclophosphamide; D000077609:O-(Chloroacetylcarbamoyl)fumagillol